High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy

Lung Cancer

Volumn 62, Issue 1, 2008, Pages 78-84

  Perng, Reury Perng ^a   Yang, Chih Hsin ^b   Chen, Yuh Min ^a   Chang, Gee Chen ^c   Lin, Meng Chih ^d   Hsieh, Ruey Kuen ^e   Chu, Nei Min ^f   Lai, Ruay Sheng ^g   Su, Wu Chou ^h   Tsao, Chao Jung ⁱ   Hsia, Te Chun ^j   Chen, Hao Cheng ^k   Chen, Chih Hung ^k   Huang, Ming Shyan ^l   Wang, Jui Long ^d   Ho, Ming Lin ^m   Chung, Chih Yuan ^m   Yu, Chong Jen ^b   Chang, Wen Cheng ^k   Kuo, Han Pin ^k   Yu, Chih Teng ^k   Lin, Zhong Zhe ^b   Kao, Woei Yau ⁿ   more..

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e MACKAY MEMORIAL HOSPITAL   (Taiwan)

^f Koo Foundation Sun Yat Sen Cancer Center   (Taiwan)

^g KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^h NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

ⁱ CHI MEI MEDICAL CENTER   (Taiwan)

^j CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^k CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^l KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^m CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

ⁿ TRI SERVICE GENERAL HOSPITAL   (Taiwan)

more..

Author keywords

Asian; Carcinoma; Caucasian; Chemotherapy; Epidermal growth factor receptor (EGFR); Erlotinib; Non small cell lung; Tyrosine kinase inhibitor (TKI)

Indexed keywords

ERLOTINIB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; TREATMENT RESPONSE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; EXANTHEMA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; QUINAZOLINES; SALVAGE THERAPY; SEX FACTORS; SMOKING; TAIWAN;

EID: 52149092350     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.02.023     Document Type: Article

References (18)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics. CA Cancer J Clin 55 (2005) 74-108
2. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
3. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker Jr. S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
4. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18 (2000) 2354-2362
5. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
6. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
7. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
8. Chang A., Parikh P., Thongprasert S., Tan E.H., Perng R.P., Ganzon D., et al. Gefitinib (Iressa) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 1 (2006) 847-855
9. Shepherd F.A., Pereira J.R., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
10. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
11. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib (ZD1839) in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial (INTACT 1). J Clin Oncol 22 (2004) 777-784
12. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib (ZD1839) in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial (INTACT 2). J Clin Oncol 22 (2004) 785-794
13. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (osi-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 5892-5899
14. Gatzemeier U., Pluzanska A., Szczesna A., Kaukel E., Roubec J., De Rosa F., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial. J Clin Oncol 25 (2007) 1545-1552
15. Chen Y.M. Clinical application of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) against non-small cell lung cancer (NSCLC). J Cancer Mol 1 (2005) 83-91
16. Jänne P.A., and Johnson B.E. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 12 Suppl. 14 (2006) 4416s-4420s
17. Schneider C., Schott-von Römer K., Gütz S., Raack B., Dierkesmann R., Laack E., et al. Biomarker analysis from TRUST, a trial of erlotinib in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 25 (2007) a7674
18. García-Velasco A., Pérez-Carrión R., de Castro J., Garrido P., García R., González-Larriba J.L., et al. Initial safety results of an open-label phase II trial of erlotinib in non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 25 (2007) a18038